Knowledge of potency and formulations of topical corticosteroids among drug vendors in the Federal Capital Territory of Nigeria
- 41 Downloads
Topical corticosteroids (TCs) are the most commonly prescribed medications in dermatology practice. Over-the-counter availability of all strengths in Nigeria has raised concerns regarding the use of TCs for non-labelled indications. Essentially, potential for misuse occurs at various levels, namely marketing, prescription, sales and end-use by patients and the lay public.
This survey aims to determine the range of TCs available in drug outlets (i.e. pharmacies and drug shops) across the Federal Capital Territory (FCT) of Nigeria and to investigate the knowledge of the salesperson on their potency and formulation.
A cross-sectional, questionnaire-based survey was conducted in drug outlets across the major satellite towns within the six area councils of the FCT from July to October 2017. The questionnaire sought to determine the brands of TCs available in pharmacies/drug shops, and obtain information on the knowledge of the potency and formulations of TCs by pharmacists/chemists. Data underwent descriptive statistical analysis.
Of the 252 drug outlets visited, 174 (69%) met the inclusion criteria. Accurate knowledge of TC potency and formulations was obtained from 33.3% and 27.6% of the respondents, respectively. A total of 454 brands of TCs were on sale in 70.7% of these outlets. Over 73% were triple-combination creams (TC–antifungal–antibacterial combination); 5% and 5.5% were TC–antibacterials and TC–antifungal combinations, respectively, while 15% were TCs alone. Only 6.6% were mild-potency TCs and 98.6% were cream formulations. The majority of the respondents stated that some of the TC prescriptions were from doctors.
Available TC formulations are skewed in favour of triple-combination creams. This is not in accordance with best clinical practice.
We wish to acknowledge Emeje Mohammed Buhari, Mary Paul and Rejoice Ojoagefu for the ground work of visiting the different pharmacies and drug shops and the drug outlet owners who consented to participate in this study.
Compliance with ethical standards
Conflict of interest
Perpetua U. Ibekwe, Eshan B. Henshaw and Grace C. Okudo declare no relevant conflicts of interest.
No external funding was received for the study.
Ethical approval was obtained from the University of Abuja Teaching Hospital Ethics Committee.
Written informed consent was obtained from each participant prior to completing the questionnaire. Confidentiality was ensured, and no incentive was given.
- 3.Rathi S. Abuse of topical steroid as cosmetic cream: a social background of steroid dermatitis. Indian J Dermatol. 2006;51:154–5.Google Scholar
- 4.Manzoor S, Shahab ud din Bukhari S, Rather S, et al. Topical steroid abuse: clinicoepidemiological profile. Int J Contemp Med Res. 2017;4(7):1454–6.Google Scholar
- 6.WHO model prescribing information: drugs used in skin diseases. Classification of topical corticosteroids. Geneva: World Health Organisation; 1997. p. 117–8. http://www.apps.who.int/medicinedocs/en/d/Jh2918e/32.html. Accessed 8 Jul 2018.
- 7.Resource Clinical. Potency of topical corticosteroids. Table showing the class and potency of topical corticosteroids in the UK; 2015. http://www.resourceclinical.com/clinical-tables/topical-corticosteroids-potency-UK-classification.html. Accessed 8 Jul 2018.
- 11.Coondoo A, Phiske M, Verma S, et al. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5:416. http://www.idoj.in/text.asp:2014/5/4/416/142483. Accessed 21 May 2018.
- 16.Chu AC. Antibacterial/steroid combination therapy in infected eczema. Acta Dermato-Venereol. 2008;Suppl. 216:28–34.Google Scholar
- 22.Shuster S. Over the counter sale of topical corticosteroids: the need for debate. Br Med J (Clin Res Ed). 1985;291(291):38–9.Google Scholar
- 25.Pande S. Steroid containing fixed drug combinations banned by government of India: a big step towards dermatologic drug safety. Indian J Drugs Dermatol. 2016;2(1):1–2.Google Scholar